Sutro Biopharma, Inc.
STRO
$0.9026
-$0.3974-30.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.81M | 8.52M | 25.71M | 13.01M | 113.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.81M | 8.52M | 25.71M | 13.01M | 113.72M |
| Cost of Revenue | -168.50M | 62.11M | 62.02M | 56.88M | -114.83M |
| Gross Profit | 183.31M | -53.59M | -36.31M | -43.87M | 228.55M |
| SG&A Expenses | 9.03M | 14.33M | 12.37M | 12.72M | 16.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.07M | 76.44M | 74.39M | 69.60M | 70.57M |
| Operating Income | -65.26M | -67.92M | -48.69M | -56.59M | 43.15M |
| Income Before Tax | -70.09M | -48.79M | -48.01M | -58.21M | 46.87M |
| Income Tax Expenses | 2.36M | -- | 8.00K | -- | 15.81M |
| Earnings from Continuing Operations | -72.44M | -48.79M | -48.02M | -58.21M | 31.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.44M | -48.79M | -48.02M | -58.21M | 31.07M |
| EBIT | -65.26M | -67.92M | -48.69M | -56.59M | 43.15M |
| EBITDA | -63.39M | -66.12M | -46.90M | -54.83M | 44.88M |
| EPS Basic | -0.88 | -0.59 | -0.59 | -0.95 | 0.51 |
| Normalized Basic EPS | -0.53 | -0.55 | -0.41 | -0.63 | 0.40 |
| EPS Diluted | -0.88 | -0.59 | -0.59 | -0.95 | 0.51 |
| Normalized Diluted EPS | -0.53 | -0.55 | -0.41 | -0.63 | 0.40 |
| Average Basic Shares Outstanding | 82.51M | 82.04M | 81.22M | 61.46M | 60.97M |
| Average Diluted Shares Outstanding | 82.51M | 82.04M | 81.22M | 61.46M | 60.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |